Shire’s $30bn move on Baxalta

Pharma giant Shire has made an unsolicited $30bn all-share offer for America’s Baxalta.

15-8-6-Shire-634

Shire is testing investors' tolerance

Pharmaceuticals giant Shire, Dublin-based and UK-listed, has made an unsolicited $30bn all-share offer for America's Baxalta. Shire said a tie-up with Baxalta would produce a group with $20bn in sales by 2020. Shire's shares fell on the news. The pharma mergers and acquisitions boom shows no sign of cooling: $400bn of transactions have been announced since January, 80% up from the same period in 2014.

What the commentators said

But there's also "a fair slug of industrial logic", said Neil Unmack on breakingviews.com. Putting the two groups together should produce a strong presence in haemophilia, and as it grows its global presence, it will gain the scale to invest in new drugs, boost prices and beef up marketing, with a view to becoming a leader in rare disease drugs. Yet Shire shareholders seem unconvinced, said Helen Thomas in The Wall Street Journal.

One worry is that Baxalta's haemophilia drugs, which account for half of sales, are about to face competition. What's more, the price is worth a hefty 16 times operating earnings, and is only likely to go higher as negotiations get underway. Shire's recent appetite for "ever bigger, more risky dealmaking is testing investors' tolerance".

Recommended

The Federal Reserve wants markets to fall – here’s what that means for investors
Stockmarkets

The Federal Reserve wants markets to fall – here’s what that means for investors

The Federal Reserve’s primary mandate is to keep inflation down, and lower asset prices help with that. So, asks Dominic Frisby – just how low will st…
25 May 2022
Four high-quality US stocks to give shelter from the storm
Share tips

Four high-quality US stocks to give shelter from the storm

Professional investor Timothy Parton of the JPMorgan American Investment Trust picks four solid US stocks to buy now.
24 May 2022
Three undervalued mid-cap stocks with attractive prospects
Share tips

Three undervalued mid-cap stocks with attractive prospects

Professional investor Katen Patel of the JPMorgan Mid Cap Investment Trust picks three fast-growing mid-cap stocks to buy now.
24 May 2022
Britain’s ten most-hated shares – w/e 20 May
Stocks and shares

Britain’s ten most-hated shares – w/e 20 May

Rupert Hargreaves looks at Britain's ten-most hated shares, and what short-sellers are looking right now.
23 May 2022

Most Popular

Everything is collapsing at once – here’s what to do about it
Investment strategy

Everything is collapsing at once – here’s what to do about it

Equity and bond markets are crashing, while inflation destroys the value of cash. Merryn Somerset Webb looks at where investors can turn to protect th…
23 May 2022
Imperial Brands has an 8.3% yield – but what’s the catch?
Share tips

Imperial Brands has an 8.3% yield – but what’s the catch?

Tobacco company Imperial Brands boasts an impressive dividend yield, and the shares look cheap. But investors should beware, says Rupert Hargreaves. H…
20 May 2022
Three high-quality FTSE 100 shares going cheap
Share tips

Three high-quality FTSE 100 shares going cheap

As stockmarkets continue to fall, bargains are starting to appear, says Rupert Hargreaves. Here, he picks three high-quality FTSE 100 shares that are …
23 May 2022